Chromocell Therapeutics Corporation (CHRO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Chromocell Therapeutics (CHRO) is engaged in a scientific and technological battle for the rapid approval of non-opioid agents while avoiding price competition. However, the business remains vulnerable due to a lack of profitability, dependence on investment, and the potential for clinical trial failures. A scaling model based on Big Pharma licenses ensures high margins. This market valuation chart for the company on GURU.Markets shows a value of , which is critical for analyzing its value.
Summary analytical data breakdowns for chromocell.com (CHRO)
- market price and analyst price targets:
- market capitalization indicators:
- book value of equity indicators:
- debt and liquidity data:
Total Debt to Capital Chromocell Therapeutics|CHRO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Chromocell Therapeutics Corp.|CHRO - Company Cumulative Debt|Debt to Book Capitalization Ratio Chromocell|CHRO - Company Long-Term Debt|Company Short-Term Debt Chromocell Therapeutics|Quick Liquidity Indicator chromocell.com
- business earnings and investment ratios data:
CHRO - Final Profit|Future Profit Chromocell Therapeutics|CHRO - Market Price to Net Income Ratio|Forward P/E Multiple Chromocell Therapeutics|CHRO - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Chromocell|CHRO - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Chromocell Therapeutics|CHRO - Earnings per share for the trailing year|Quarterly EPS earnings growth chromocell.com|CHRO - Earnings growth in current year|Net earnings per share growth forecast for next year Chromocell Therapeutics
Initial company analysis:CHRO (Chromocell Therapeutics Corporation)
Chromocell Therapeutics (CHRO) utilizes robotic platforms for high-throughput testing of neural cells, which requires significant capital expenditures in infrastructure. The enterprise value to EBITDA ratio quantifies the efficiency of these assets, excluding the impact of debt load and the tax regime. Analyzing the EV/EBITDA chart against historical data allows for an assessment of the company's degree of undervaluation and helps define the boundaries of investment risk.
Who Chromocell Therapeutics competes with
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|Business Value to Operating Income Before Depreciation NBIX|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA axsome.com|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Xenon Pharmaceuticals Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viking Pharma|Company Value to EBITDA Supernus Corp SUPN|EV/EBITDA Multiple CPRX|Enterprise Value to EBITDA Ratio denalitherapeutics.com DNLI|EV/EBITDA Multiple HRMY (Harmony Biosciences Holdings, Inc.)|Biohaven Ltd (BHVN) - Company Value to EBITDA|AMLX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRVI: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Praxis Precision Medicines (PRAX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AVXL (anavex.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio CBLL|PRTA: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio ALEC (Alector, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ANNX|EV/EBITDA Multiple OMER (Omeros)|Business Value to Operating Income Before Depreciation NGNE|AC Immune SA - EV/EBITDA Multiple|Company Value to EBITDA Voyager Therapeutics Inc|Neumora Therapeutics Inc (NMRA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Scilex Holding Company, Inc. - Business Value to Operating Income Before Depreciation|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|EV/EBITDA Multiple Alpha Cognition Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cognition Therapeutics, Inc. (CGTX)|IKT: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple SAVA (Cassava)|Assertio Holdings (ASRT) - Company Value to EBITDA|COYA: Enterprise Value to EBITDA Ratio|VTGN - EV/EBITDA Multiple|OVID (ovidrx.com) - Enterprise Value to EBITDA Ratio|ABOS: Enterprise Value to Operating Income Before Depreciation Ratio|CRVO (CervoMed Inc) - EV/EBITDA Multiple|Alterity Therapeutics Ltd (ATHE) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CLNN|Enterprise Value to EBITDA Ratio pepgen.com PEPG|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|Total Company Value to Operating Income Before Depreciation Ratio Relmada Therapeutics Inc (RLMD)|Annovis Bio Corp - EV/EBITDA Multiple|Grace Therapeutics, Inc. (GRCE) - Enterprise Value to EBITDA Ratio|AIFF: EV/EBITDA Multiple|Klotho Neurosciences - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd|RVPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MetaVia Inc (MTVA)|NRXS - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Helius Medical Technologies HSDT|PASG: Enterprise Value to Operating Income Before Depreciation|Neuphoria - EV/EBITDA Multiple|Company Value to EBITDA Minerva Neurosciences Inc|ATHA (Athira) - Enterprise Value to EBITDA Ratio|Addex (ADXN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alzamend Neuro Inc.|CYCN: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protagenic Therapeutics (PTIX)|KTTA - Company Value to EBITDA|EV/EBITDA Multiple CRGT (Cortigent)|ATXI - Enterprise Value to EBITDA Ratio|Brainstorm Cell - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CARA (caratherapeutics.com)|eliemtx.com (ELYM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Intra-Cellular Therapies, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharma|Company Value to EBITDA Marinus Pharma MRNS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech, Inc. (NKGN)|Enterprise Value to EBITDA Ratio neurobopharma.com NRBO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sage Therapeutics SAGE|Synaptogenix Inc. (SNPX) - Company Value to EBITDA|Trevena, Inc - EV/EBITDA Multiple|Vigil Neuroscience (VIGL) - Enterprise Value to EBITDA Ratio|WENA: EV/EBITDA Multiple|Company Value to EBITDA cerevel.com (CERE)
